LyGenesis is a clinical-stage biotechnology company based in Pittsburgh, PA that develops cell therapies which use patients' lymph nodes as bioreactors to regenerate functioning ectopic organs. Its lead allogeneic cell therapy program is in a Phase 2a clinical trial for patients with end-stage liver disease (ClinicalTrials.gov Identifier: NCT04496479). The company's pipeline also includes programs to produce an ectopic thymus, pancreas (for Type 1 diabetes), and kidney (for end-stage renal disease). LyGenesis raised financing to support clinical and pipeline advancement and intends to use the proceeds to complete its Phase 2a trial and advance its cell therapy programs. The company is positioned as a clinical-stage developer advancing multiple organ-regenerative therapies through human trials. No revenue or user metrics were reported in the article. LyGenesis is a biotechnology company developing an organ regeneration platform that uses a patient’s lymph nodes as bioreactors to regrow functioning ectopic organs. Its lead allogeneic cell therapy program targets liver regeneration for patients with end stage liver disease. The company plans to move that lead program into clinical development, beginning with a Phase 2a clinical trial in 2020. LyGenesis’s drug development pipeline also includes programs for thymus, pancreas, and kidney regeneration. The company is led by Co-Founder and CEO Michael Hufford. The recent financing provides capital to support the transition of the lead program into the clinic. LyGenesis is a Pittsburgh-based biotechnology company developing an organ regeneration technology platform that enables a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Its lead preclinical program focuses on liver regeneration for patients with end stage liver disease; other therapeutic targets include the thymus, pancreas, and kidney. The company raised $3M in a Series A financing from Juvenescence. The financing will enable LyGenesis to complete the final preclinical work required to enable human clinical trials, which will initially focus on patients with end stage liver disease. In conjunction with the investment, Greg Bailey, MD, Co‑Founder and CEO of Juvenescence, will join LyGenesis’ Board of Directors. LyGenesis’ scientific work is built on academic research by Eric Lagasse, PharmD, PhD, who serves as Chief Scientific Officer; the company is led by Michael Hufford, PhD, Chief Executive Officer, and Paulo Fontes, MD, FACS, Chief Medical Officer.

Total raised

$26M

Funding rounds

3

Latest round

Series A

Latest activity

Oct 2023